LUPIN Pharmaceuticals, Inc.

Presented by-Abhishek Pandey15020241005

Submitted to-Prof. Smita SantokiTowards Operations Assignment

About Lupin

• Established in 1968, by Dr. Deshbandu Gupta

• Company named after Lupin flower, which is known for its theraupatic nature.

• First gained reputation as the largest supplier of TB drugs

• Today is a leading global player in Anti-TB, Cephalosporins (anti-infectives) and Cardiovascular drugs (ACE-inhibitors and cholesterol reducing agents) and has a notable presence in the areas of diabetes, anti-inflammatory and respiratory therapy

• For the financial year ended 31st March 2015, Lupin's Consolidated turnover and Profit after Tax were Rs. 125,997 million (USD 2.06 billion) and Rs. 24,032 million (USD 393 million) respectively

• World leader as “branded generics"

“Mission/Vision

Lupin's mission is to become a transnational pharmaceutical company through the development and introduction of a wide portfolio of

branded and generic products in key markets.

Products

Generics Specialty API• More than 75 FDA

approved products• ANDAs in following

areas- a. cephalosporinsb. Cardiovascularc. Controlled release ANDAd. Paragraph IVs

• Committed to child care

• Drug - SUPRAX®• Dedicated sales

force to call upon pediatricians

• leading manufacturer of cephalosporin API’s

• wide range of ACE-inhibitors and cholesterol reducing agents

Market Watch

Global Capabilities footprint

Global HQ, Mumbai

Market Presence

2004 Lupin was operating only from India. Its presence to other countries was through trade partnerships and direct-to-market initiatives

2005 Lupin was the last entrant into US market amongst Indian Pharma majors

2007 acquired Kyowa in 2007 to enter Japanese market

2008 bought Hormosan Pharma GmbH to improve its position in Europe. This has helped in strenghtening its presence in European markets

Lupin acquired Generic Health to enter into Australian markets

2009 Acquires Multicare Pharma in Philippines to penetrate into SE Asia

2011 Acquires I’rom in Japan to break into top 10 generic brands in Japan

Growth through M&A

2012 Enters strategic marketing parnership with Sanofi to foray into neurology (Philipines)

2014 entered into JV with Yoshindo to create YL Biologics. This is to develop its portfolio in biosimilars

Acquires Laboratories Grin in Mexico to serve Mexico and Latin America

bought Gavis to become the 5th largest pharma company in US

2015 bought 40% stake of Pharma Dynamics in South Africa. This has made it the 4th largest generic company in SA

Buys  Medquímica Indústria Farmacêutica, Brazil for further penetration in Latin America

Purchases Biocom, to foray into Russian market

Growth through M&A (contd.)

Growth Drivers

Organic Inorganic

Maximizing current / near term pipeline

Operational / Commercial excellence

Pipeline evolution into complex generics / specialty

Leveraging our investments across geographies

Specialty

Geographic diversification

Tech Platforms

Scale

Growth strategy

US India Japan Europe Other Markets• Entry through

generic drugs• Expansion

through strategic acquisitions

• Portfolio expansion through R&D in Pune

• New therapy areas

• Entry through generic drugs

• Expansion through strategic acquisitions

• Biosimilar through JV

• Entry through trade partners

• German acquisition helps in central distribution

• Establish trade partners

Operational Strategy• Vertically Integrated and diversified manufacturing platform

• Control over entire supply chain right from earlyintermediates

• Ability to manufacture key products from two or more sites

• Extensive capabilities in multiple dosage forms – solids,semi-solids, liquids, injectables and more

• Consistent Compliance track record

• Responsive and agile supply chain

• Differentiated market entry approach

• Focus on margin enhancement and overhead optimization

• Challenges – to cater the growing new markets

Latest in Media!

Lupin launches first ever Duloxetine 40mg Delayed-Release Capsules in the US (September 3rd, 2015)

Pharma major Lupin Limited announced today that its subsidiary Lupin Pharmaceuticals, Inc. (Lupin) has launched its Duloxetine 40 mg Delayed-Release (DR) Capsule, which is the first and only generic Duloxetine formulation to become available in 40 mg dosage strength. Lupin is excited to bring this new strength to market, as it adds to the currently-available dosing options for greater flexibility of treatment.

Lupin is the only generic manufacturer to offer all Duloxetine dosage strengths - the 20 mg, 30 mg, 60 mg, and now the newest 40 mg. Lupin's generic Duloxetine 40 mg DR capsules are therefore the first and only capsule available for patients in this dosage strength. 

Cymbalta® Delayed-Release Capsules 20 mg, 30 mg and 60 mg strengths had annual U.S sales of approximately USD 1.05 billion (Brand + Generics - IMS MAT June 2015).

Bibliography

• http://www.lupinpharmaceuticals.com/

• http://www.lupinpharmaceuticals.com/newsroom.htm

• http://articles.economictimes.indiatimes.com/2010-04-30/news/27578338_1_kamal-k-sharma-lupin-generic-players

• http://www.pharmacytimes.com/publications/supplement/2012/Generic-Supplement-2012/LupinPharmaceuticals_2012

• http://old.businessworld.in/news/business/pharma/how-lupin-got-its-mojo-back/379072/page-1.html

• http://www.thehindubusinessline.com/companies/lupin-looks-at-bigticket-alliances-acquisition-in-india/article2415313.ece

• https://en.wikipedia.org/wiki/Lupin_Limited

Thanks!Any questions?

You can find me at:Abhishek.Pandey@siib.ac.in